The greater susceptibility to Prima-1 ± 3-BrPA in hypoxic mutant NRAS MelJuso melanoma (Summary, Fig. 10), suggests that agents like Prima-1 + 3-BrPA, may help attenuate the frequent acquisition of resistance to targeted therapy against V600E BRAF-mutated tumors which acquire NRAS mutations [52]. This evidence concerns the gene BRAF and melanoma.